Zusammenfassung
Pluripotente Stammzellen besitzen ein unbegrenztes Selbsterneuerungs- und Differenzierungspotenzial zur Gewinnung sämtlicher Zellarten des menschlichen Organismus. Damit stellen sie ein einzigartiges Modell für die Beantwortung entwicklungsbiologischer Fragestellungen wie auch für die Zelltherapie und regenerative Medizin dar. Dem Arzt und Stammzellforscher S. Yamanaka gelang erstmals die Reprogrammierung somatischer Zellen zu sog. induzierten pluripotenten Stammzellen durch die ektope Expression der Transkriptionsfaktoren Oct4 („Octamer-binding transcription factor 4“), Sox2 („sex determining region Y – box 2“), Klf4 („Kruppel-like factor 4“) und c-Myc („v-myc myelocytomatosis viral oncogene homolog“). Damit revolutionierte er die Möglichkeiten in der regenerativen Medizin. Insbesondere eröffneten sich durch die Anwendung dieser Techniken im patienten- bzw. krankheitsspezifischen Kontext neue Möglichkeiten zur Modellierung von Krankheiten und zur individualisierten Testung von Medikamenten. Zudem rückt das sog. therapeutische Klonen einen ganzen Schritt näher. Die vorliegende Übersichtsarbeit soll daher dem klinisch tätigen Arzt einen Überblick über den Stand der Forschung und die klinische Anwendung pluripotenter Stammzellen geben.
Abstract
Pluripotent stem cells possess a remarkable unlimited self-renewal capacity and offer unparalleled in vitro differentiation potential. This provides a unique model system not only to study early human development but also gives renewed hope in terms of developing cell therapies and regenerative medicine. S. Yamanaka, a medical doctor and researcher, reported the possibility of reprogramming somatic cells to so-called induced pluripotent stem cells via the ectopic expression of four transcription factors, namely Oct4, Sox2, Klf4 and c-Myc. This Nobel Prize winning work has since revolutionized stem cell research and paved the way for countless new avenues within regenerative medicine. This includes disease modeling in a patient-specific context with the ultimate aim of individually tailored pharmaceutical therapy. Additionally, genetic correction studies have rapidly increased in basic science and thus there is hope that these can be effectively and efficiently translated into clinical applications. Addressing the medical community this review gives a broad general overview about the state of the research field and possible clinical applications of pluripotent stem cells.
Literatur
Aasen T, Raya A, Barrero MJ et al (2008) Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes. Nat Biotechnol 26:1276–1284
Amabile G, Welner RS, Nombela-Arrieta C et al (2013) In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. Blood 121:1255–1264
Carvajal-Vergara X, Sevilla A, D’Souza SL et al (2010) Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465:808–812
Cayo MA, Cai J, Delaforest A et al (2012) JD induced pluripotent stem cell-derived hepatocytes faithfully recapitulate the pathophysiology of familial hypercholesterolemia. Hepatology 56:2163–2171
Choi SM, Kim Y, Shim JS et al (2013) Efficient drug screening and gene correction for treating liver disease using patient-specific stem cells. Hepatology 57:2458–2468
Egawa N, Kitaoka S, Tsukita K et al (2012) Drug screening for ALS using patient-specific induced pluripotent stem cells. Sci Transl Med 4:145ra104
Gordon PH, Moore DH, Miller RG et al (2007) Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 6:1045–1053
Hanna J, Cheng AW, Saha K et al (2010) Human embryonic stem cells with biological and epigenetic characteristics similar to those of mouse ESCs. Proc Natl Acad Sci U S A 107:9222–9227
Hanna J, Wernig M, Markoulaki S et al (2007) Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318:1920–1923
Hoing S, Rudhard Y, Reinhardt P et al (2012) Discovery of inhibitors of microglial neurotoxicity acting through multiple mechanisms using a stem-cell-based phenotypic assay. Cell Stem Cell 11:620–632
Kaufman MH, Robertson EJ, Handyside AH et al (1983) Establishment of pluripotential cell lines from haploid mouse embryos. J Embryol Exp Morphol 73:249–261
Kriks S, Shim JW, Piao J et al (2011) Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson’s disease. Nature 480:547–551
Li Y, Tsai YT, Hsu CW et al (2012) Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med 18:1312–1319
Liang P, Lan F, Lee AS et al (2013) Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 127:1677–1691
Linta L, Stockmann M, Kleinhans KN et al (2012) Rat embryonic fibroblasts improve reprogramming of human keratinocytes into induced pluripotent stem cells. Stem Cells Dev 21:965–976
Loh YH, Agarwal S, Park IH et al (2009) Generation of induced pluripotent stem cells from human blood. Blood 113:5476–5479
Matsa E, Rajamohan D, Dick E et al (2011) Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J 32:952–962
Mayshar Y, Ben-David U, Lavon N et al (2010) Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7:521–531
Patel M, Yang S (2010) Advances in reprogramming somatic cells to induced pluripotent stem cells. Stem Cell Rev 6:367–380
Raya A, Rodriguez-Piza I, Guenechea G et al (2009) Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. Nature 460:53–59
Reinhardt P, Schmid B, Burbulla LF et al (2013) Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression. Cell Stem Cell 12:354–367
Si-Tayeb K, Noto FK, Nagaoka M et al (2010) Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology 51:297–305
Smits AM, Van Laake LW, Den Ouden K et al (2009) Human cardiomyocyte progenitor cell transplantation preserves long-term function of the infarcted mouse myocardium. Cardiovasc Res 83:527–535
Stockmann M, Linta L, Fohr KJ et al (2013) Developmental and functional nature of human iPSC derived motoneurons. Stem Cell Rev 9:475–492
Streckfuss-Bomeke K, Wolf F, Azizian A et al (2013) Comparative study of human-induced pluripotent stem cells derived from bone marrow cells, hair keratinocytes, and skin fibroblasts. Eur Heart J 34:2618–2629
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676
Thomson JA, Itskovitz-Eldor J, Shapiro SS et al (1998) Embryonic stem cell lines derived from human blastocysts. Science 282:1145–1147
Tulpule A, Kelley JM, Lensch MW et al (2013) Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell 12:727–736
Weidgang CE, Russell R, Tata PR et al (2013) TBX3 directs cell-fate decision toward mesendoderm. Stem Cell Reports 1:248–265
Wootla B, Denic A, Warrington AE et al (2012) Need for a paradigm shift in therapeutic approaches to CNS injury. Expert Rev Neurother 12:409–420
Yang YM, Gupta SK, Kim KJ et al (2013) A small molecule screen in stem-cell-derived motor neurons identifies a kinase inhibitor as a candidate therapeutic for ALS. Cell Stem Cell 12:713–726
Yu DX, Marchetto MC, Gage FH (2013) Therapeutic translation of iPSCs for treating neurological disease. Cell Stem Cell 12:678–688
Zou J, Maeder ML, Mali P et al (2009) Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell 5:97–110
Einhaltung ethischer Richtlinien
Interessenkonflikt. S. Liebau, M. Stockmann, A. Illing, T. Seufferlein und A. Kleger geben an, dass kein Interessenkonflikt besteht. Dieser Beitrag beinhaltet keine Studien an Menschen oder Tieren.
Author information
Authors and Affiliations
Corresponding authors
Additional information
S. Liebau und M. Stockmann haben in gleichem Maße zu dieser Arbeit beigetragen.
Rights and permissions
About this article
Cite this article
Liebau, S., Stockmann, M., Illing, A. et al. Induzierte pluripotente Stammzellen. Internist 55, 460–469 (2014). https://doi.org/10.1007/s00108-013-3397-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00108-013-3397-2